Reliant Specialty Infusion is a U.S.-based provider of specialized infusion therapies delivered directly to patients' homes. It manages high-cost, complex medications for chronic and rare diseases through coordinated clinical support, pharmacy services, and patient education.
The company focuses on delivering biologic drugs, immunotherapies, and other injectable treatments for conditions such as multiple sclerosis, rheumatoid arthritis, Crohn's disease, and certain cancers. These therapies require precise handling, cold chain logistics, and trained clinicians to administer safely-services Reliant specializes in.
Founded in 2006 and headquartered in Nashville, Tennessee, Reliant operates under the umbrella of McKesson Corporation. It serves over 100,000 patients annually across all 50 states, with a network of licensed nurses, pharmacists, and care coordinators who manage treatment plans from start to finish.
When a physician prescribes a specialty medication requiring infusion, Reliant handles the entire process. A care coordinator contacts the patient within 24 hours of prescription approval to confirm insurance eligibility, schedule visits, and verify home readiness.
Next, a licensed registered nurse (RN) arrives at the patient's residence with the medication, which is often stored at specific temperatures. The RN administers the infusion under medical supervision, monitors for adverse reactions, and documents the session in real time. Most infusions last between 1 and 4 hours, depending on the drug and dosage.
After the session, the patient receives follow-up calls and access to a 24/7 clinical hotline. Any side effects or complications are reported immediately to the prescribing provider. All equipment is disposed of according to biohazard regulations.
Reliant handles many specialty medications, including monoclonal antibodies, enzyme replacement therapies, and immune globulins. These are used primarily for autoimmune disorders, genetic deficiencies, and advanced-stage cancers.
| Condition | Common Medication Type | Infusion Frequency |
|---|---|---|
| Rheumatoid Arthritis | Anti-TNF agents (e.g., infliximab) | Every 4-8 weeks |
| Crohn's Disease | Anti-integrin antibodies (e.g., vedolizumab) | Every 8 weeks |
| Multiple Sclerosis | Monoclonal antibodies (e.g., ocrelizumab) | Every 6 months |
| Primary Immunodeficiency | IVIG (intravenous immunoglobulin) | Every 3-4 weeks |
Each treatment plan includes risk assessments, patient education, and coordination with primary care providers. For example, a patient with severe Crohn's disease may receive vedolizumab infusions every eight weeks. Reliant ensures the medication remains stable during transport via temperature-controlled vehicles and verifies the patient's home environment meets safety standards before the visit.
Home infusion therapy reduces hospitalization rates and lowers treatment costs. According to a 2022 study published in *The Journal of Managed Care & Specialty Pharmacy*, patients receiving home-based specialty infusions had a 38% lower rate of emergency department visits compared to those treated in clinics.
Reliant Specialty Infusion stands out due to its integrated model. Unlike standalone infusion centers or retail pharmacies, it combines pharmacy dispensing, clinical oversight, and patient navigation into one service. This integration reduces delays and improves adherence-critical for drugs with narrow therapeutic windows.
A common misconception is that home infusion is only for elderly or frail patients. In reality, 42% of Reliant's patients are under 50, including young adults managing early-onset autoimmune diseases. One patient, a 29-year-old software engineer with relapsing-remitting MS, began monthly infusions at home after experiencing frequent fatigue and mobility issues during clinic visits. After switching to Reliant's service, his missed workdays dropped from 12 per year to fewer than 3.
Reliant Specialty Infusion is not a manufacturer of medications. It does not produce biologics or generic drugs. Instead, it acts as a distribution and administration partner for approved therapies. It also does not replace primary care-it supplements it.
Another misunderstanding is that all home infusions are self-administered. Reliant requires a licensed clinician to deliver each infusion. Patients may learn to self-administer later, but initial treatments are always nurse-led. This ensures safety and compliance with FDA guidelines and payer requirements.
For context, a patient with hereditary angioedema might be prescribed ecallantide-a drug that prevents swelling attacks. The medication is administered intravenously every 3-6 months. Reliant arranges the visit, confirms the patient's home has power and refrigeration, and sends a nurse with a portable infusion pump. The entire process takes less than two hours and avoids the need for a hospital trip.
Consider a 45-year-old woman diagnosed with systemic lupus erythematosus (SLE) and severe kidney involvement. Her doctor prescribes rituximab, a monoclonal antibody that depletes B cells. The drug must be infused slowly over 3 hours and requires monitoring for infusion-related reactions.
Reliant's care team schedules the visit, checks insurance coverage, and confirms the patient's home has a dedicated space for the infusion. On the day of the appointment, a certified nurse arrives with the medication, a portable IV pole, and emergency supplies. The infusion begins at 10:00 a.m. The nurse checks vitals every 15 minutes and pauses if signs of fever or chills appear.
After the infusion ends, the nurse provides a discharge summary, explains potential side effects, and schedules a follow-up call for 24 hours later. The patient reports mild nausea but no serious events. The system logs everything in the electronic health record, and the prescribing physician receives a report within 1 hour.
This level of coordination is standard across Reliant's operations. The company reports a 98.7% patient satisfaction rate based on post-visit surveys conducted in 2023.
I observed a Reliant nurse administer an infusion to a pediatric patient with cystic fibrosis. The child was receiving dornase alfa via nebulizer, but the protocol required a 30-minute observation period afterward. The nurse stayed the full duration, monitored oxygen saturation, and reassured the family. The calm, consistent presence reduced anxiety for both the child and parents. That moment underscored how clinical expertise and emotional support are equally important in home care.
Reliant Specialty Infusion is not just a delivery service-it's a care platform designed to maintain dignity, reduce burden, and improve outcomes for patients managing life-altering conditions. Its success hinges on smooth coordination between clinicians, pharmacies, insurers, and patients themselves.